Prana Biotechnology yesterday announced its financial results for the 12 months to June 30, 2015.
Author: Kerry Rowe
Prana Biotechnology has today announced the safety outcomes of the IMAGINE Extension study in patients with Alzheimer’s disease. A 250mg dose of PBT2 was safe and well tolerated over a 2 year period. The independent Data Safety Monitoring Board did not identify any safety concerns related to PBT2.
Prana Biotechnology Limited has today announced that it has received a $6.8 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.